There are few data available on the prevalence of hyperuricemia and its possible association with cardiovascular diseases among the very elderly population. The main part of this study enrolled 320 very elderly hospitalized patients (aged 86.4 ± 5.0 years; females, 78.1%; males, 21.9%) with coronary artery disease (CAD) and arterial hypertension (AH). The second part of the study involved 48 patients younger than 60 years, who were hospitalized with CAD diagnosis for coronary angiography study. Patients with gout were excluded from analysis. Hyperuricemia was defined as serum uric acid (SUA) more than 340 μmol/l in women and 420 μmol/l in men. Elevated serum uric acid (SUA) levels were detected in 37.4% of 320 elderly patients. Hyperuricemia was significantly more common in women (in 41.5% of cases) than in men (in 25%) (p = 0.02). In the group of very elderly patients, there was a clear correlation between hyperuricemia and clinically significant chronic heart failure (OR = 5.0; 95% CI = 2.4-10.7; p < 0.0001), as well as with stroke in history (OR = 1.9; 95% CI = 1.0-3.4; p = 0.03). Hyperuricemia remained significant risk factor of heart failure in the multiple regression analysis (p < 0.001). Atrial fibrillation was significantly more frequently diagnosed in patients with hyperuricemia compared with patients with normal levels of uric acid (OR = 2.2; 95% CI = 1.3-3.6; p = 0.001). A pronounced positive correlation was found between the SUA levels and the diameter of the left atrium (r = 0.3; p = 0.000003). In the group of 48 CAD patients under 60 years of age, hyperuricemia was significantly associated with myocardial infarction (OR = 8.8; 95% CI = 2.0-38.9; p = 0.002) and chronic heart failure (OR = 6.9; 95% CI = 1.8-26.3; p = 0.003). In general, the obtained results indicate a significant prevalence of hyperuricemia in people with CAD. A significant relationship between the increased SUA levels and the development of some cardiovascular diseases was found.
Introduction
Cardiovascular diseases occupy a leading place in the overall structure of morbidity, disability, and mortality in the Russian Federation and in many other countries. In Russia, about 1 million people die from these diseases each year, and the leading causes of death are coronary artery disease (CAD) and cerebrovascular disease [1] . Traditional risk factors such as smoking and alcohol abuse, physical inactivity, and poor nutrition, leading to obesity, dyslipidemia, and hyperglycemia, make a significant contribution to this statistic. Of particular importance is arterial hypertension diagnosed in more than 40% of the adult population of the Russian Federation. The aging of population and the associated accumulation of cardiovascular diseases also play essential role. In recent years, the development of novel therapeutic approaches led to significant progress in the treatment of cardiovascular diseases. However, despite this progress, the mortality of patients in this group remains very high. Therefore, analysis of additional risk factors for cardiovascular pathologies, including hyperuricemia, is of significant theoretical and practical interest.
The increased concentration of uric acid in the blood is associated not only with the risk of gout, but also with such pathological processes as arterial hypertension, atherosclerosis, and chronic kidney disease [2] [3] [4] [5] [6] . However, there is no commonly accepted theoretical concept that explains the relationship between hyperuricemia and cardiovascular diseases. A number of concepts have been proposed that interpret the possible effect of uric acid on the onset and progression of some cardiovascular diseases. Thus, based on the results of some clinical and experimental studies, it was suggested that hyperuricemia plays a significant role in the development of oxidative stress [3, 6] . According to other researchers, the increased uric acid level in patients with cardiovascular diseases is only a marker of oxidative stress in conditions of local ischemia [7] .
In several studies, it has been demonstrated that an excess of uric acid either initiates or stimulates the process of endothelial dysfunction and vascular remodeling. Uric acid is able to penetrate endothelial cells and cause vasoconstriction and endothelial dysfunction. In addition, the elevated serum levels of uric acid are associated with the increased adhesive and aggregation capacity of platelets, the enhanced proliferation of vascular smooth muscle cells, and the progression of the atherosclerotic process [2-4, 6, 8-10] .
A number of studies have also demonstrated a proinflammatory effect of uric acid. Thus, it was reported that serum uric acid levels directly correlate with the concentration of proinflammatory mediators such as C-reactive protein, interleukin-6, and tumor necrosis factor-alpha [11, 12] . The relationship between the levels of uric acid and proinflammatory mediators was found not only in patients with severe cardiovascular pathology, but also in patients with subclinical symptoms of atherosclerosis [13] .
The increased SUA level plays an important role in the development of some metabolic disorders such as insulin resistance, obesity, and dyslipidemia. Therefore, a number of authors consider hyperuricemia as a key component of the metabolic syndrome [2, 7] .
It should be noted that the changes in lifestyle of people in different countries over the past decades have contributed to a significant increase in the concentration of uric acid in the blood and a rather high prevalence of hyperuricemia in the population [4] . It is significant that the level of uric acid increases markedly with age, both in men and women. The general aging of the population and the associated multiple comorbidities make it quite relevant to study hyperuricemia and its possible relationships with cardiovascular diseases in elderly people [14] . In light of such contradictory data on the role of uric acid in the pathogenesis of cardiovascular diseases, it was interesting to study the relationship between hyperuricemia and cardiovascular diseases in seniors.
The main objective of this work is to study the prevalence of hyperuricemia and assess the possible relationship between elevated levels of uric acid and various cardiovascular diseases in elderly people (> 75 years old) compared with the group of CAD patients younger than 60 years.
Materials and Methods
This study is a one-time cross-sectional study. The main part of this study was performed in the Hospital of War Veterans №3 (Moscow). Participants of the study were 320 men and women over 75 years old hospitalized with diagnoses of coronary artery disease (CAD) and arterial hypertension. Diagnosis of coronary artery disease in very elderly patients was based on myocardial infarction or percutaneous interventions in history as well as on the presence of typical stable angina pectoris. The second part of the study was conducted in the Vladimirsky Hospital (Moscow) and involved 48 patients younger than 60 years, who were hospitalized in the hospital with CAD diagnosis for coronary angiography study. The main exclusion criteria in both groups of patients were the presence of gout and clinically significant chronic kidney disease (IV-V stage).
To assess the patient's condition, we used standard clinical methods of examination of persons suffering from CAD and hypertension, as well as echocardiography. The level of systolic and diastolic blood pressure was measured in patients in a sitting position. The body weight and height of patients were measured (if patient was able to stand on the scales), and body mass index (BMI) was calculated by the formula weight/ height 2 (kg/m 2 ). BMI values from 18.5 to 24.9 were considered as indicators of normal body mass; BMI values between 25 and 29.9 indicated excessive body mass; obesity was diagnosed if BMI was more than 30 kg/m 2 .
Standard laboratory blood and urine tests were also performed. The serum levels of glucose, total cholesterol, and triglycerides were determined. Hypercholesterolemia was diagnosed if the total cholesterol level exceeded 6.2 mmol/l, and hypertriglyceridemia if triglyceride level exceeded 2.28 mmol/l. Creatinine clearance was calculated using the Cockroft-Gault formula: Cl cr (ml/min) = a × (140 − age) × weight (kg)/serum creatinine (μmol/l), where a = 1.23 for men and a = 1.04 for women.
In all hospitalized patients with CAD, the serum uric acid (SUA) level was examined. SUA levels in the ranges of 140-340 and 200-420 μmol/l were considered normal for women and men, respectively. The values exceeding 340 μmol/l in women and 420 μmol/l in men were considered as indicators of hyperuricemia.
The obtained data were analyzed and presented using the methods of descriptive statistics (mean, standard deviation, median, minimum, and maximum values for quantitative variables; number and distribution for qualitative variables). When comparing groups, non-parametric methods were used (Mann-Whitney test, chi-square test, or Fisher's exact test). Correlation analysis was performed using the Spearman test. The likelihood of cardiovascular risk was assessed using the odds ratio; the obtained values were presented with the corresponding two-sided 95% confidence intervals. P< 0.05* was used to indicate statistical significance. The data were analyzed using Statistica (version 10.0) and SPSS (version 21) software tools.
Results
The main study involved 320 patients with CAD and arterial hypertension, including 258 (80.7%) women and 62 (19.3%) men. The age of patients ranged from 75 to 97 years, averaging 86.5 ± 4.9 years. Most patients were over 80 years old, and only 10.5% of patients were between 75 and 80 years old. Along with CAD and arterial hypertension, the patients included in the study had multiple comorbidities typical for this age. A history of myocardial infarction was recorded in 23.7% of patients, acute stroke in 14.4% of patients. Clinically significant chronic heart failure (CHF), corresponding to III-IV functional class according to the NYHA classification, was diagnosed in 15.8% of patients. Diabetes mellitus or impaired glucose tolerance was found in 21.9% of patients. The most common pathology was atrial fibrillation, recorded in 32.4% of patients.
The elevated serum uric acid levels were found in 37.4% of patients in this group. The average concentration of uric acid was 343.5 ± 111.0 μmol/l in the whole group, 447.2 ± 91.2 μmol/l in patients with hyperuricemia, and 278.4 ± 62.2 μ mol/l in patients without hyperuricem ia. Hyperuricemia was significantly more frequently observed in women (in 41.5% of cases) than in men (in 25%) (p = 0.02) ( Fig. 1 ). The average level of uric acid in women was almost at the upper limit of norm, amounting to 338.3 μmol/l (the upper limit of norm is 340 μmol/l), while for men the average level was 365.4 μmol/l (the upper limit of norm is 420 μmol/l). Of note, only in 25% of women the concentration of uric acid was less than 268 μmol/l.
Comparative characteristics of two subgroups of patients with the normal and elevated levels of uric acid are presented in Table 1 . The most expressed differences between the subgroups are related to clinically significant chronic heart failure: this complication was observed in 26.8% of patients with hyperuricemia and only in 8.5% of patients with normal levels of uric acid (p < 0.0001). In addition, in the presence of hyperuricemia, atrial fibrillation and a history of stroke were significantly more frequently diagnosed (p = 0.001 and p = 0.03, respectively). In the studied group of patients, the level of uric acid increased with increasing azotemia: the average levels of creatinine and urea were significantly higher in patients with hyperuricemia compared to persons with normal levels of uric acid (p < 0.0001).
Patients with hyperuricemia suffered from diabetes mellitus more often than patients with normal levels of uric acid (28.5% and 18.5% respectively; p = 0.03). However, no significant differences were found between the subgroups of patients in terms of serum glucose level (p = 0.2).
In general, overweight and obesity were observed significantly more often in patients with hyperuricemia, but in women the relationship between body mass index and uric acid level was not so expressed (p = 0.08). No significant differences in the levels of total cholesterol and triglycerides were detected.
Some important relationships between hyperuricemia and cardiovascular pathology identified in this study are presented in Table 2 and in Fig. 2 .
Using regression analysis, we revealed that hyperuricemia may be an independent risk factor for the development of chronic heart failure (p < 0.001).
Differences in the contractile function of the myocardium between subgroups of patients were not found. The ejection fraction averaged 59.9 ± 5.3% in persons with hyperuricemia, and 60.5 ± 4.1% in persons without hyperuricemia (p = 0.2). However, even in the presence of clinically significant chronic heart failure, the majority of patients had normal ejection fraction values. Such a situation corresponded to CHF with a preserved ejection fraction.
In the whole group, dilatation of the left atrium was found in 73.3% of patients, and hyperuricemia increased the likelihood of this condition. Thus, according to echocardiography, dilatation of the left atrium was detected in 80.6% of patients with hyperuricemia, and in 68.8% of patients without hyperuricemia (p = 0.03). The average diameter of the left atrium was 44.6 ± 4.9 and 42.8 ± 4.3 cm in patients with and without hyperuricemia, respectively (p = 0.0006). A pronounced positive correlation was observed between the level of uric acid in the serum and the diameter of the left atrium (r = 0.3; p = 0.000003). Correlation analysis also revealed statistically significant relationships between the level of uric acid and two other biochemical parameters, creatinine level (r = 0.5; p < 0.0001) and urea level (r = 0.5; p < 0.0001). In addition, a significant correlation was found between serum uric acid concentration and body mass index (r = 0.2; p = 0.03). No significant correlation of uric acid level with other studied parameters was found.
It is noteworthy that significant positive correlation between uric acid and such proinflammatory cytokine as tumor necrosis factor-alfa (TNF-alfa) was found (r = 0.5; p = 0.00004).
Due to some specific features of the studied group of patients and, in particular, the presence of significant intellectual and mental disorders, it was problematic to reliably assess the impact of such risk factors as alcohol consumption and smoking. It is important to note that the absolute majority of patients had very low physical activity (up to long-term immobilization); many of them could not walk more than 100 m without stopping. The vast majority of study patients (72.9%) received low doses of acetylsalicylic acid in hospital. Treatment with angiotensin-converting-enzyme inhibitors was administered to 31.6% of patients; and angiotensin II receptor blockers (mainly losartan) to 41.6% of patients. βadrenergic blockers (mainly bisoprolol) were prescribed in 70.4% of patients. Diuretics were administered to 55.5% of patients; 36.2% of patients received indapamide, and loop diuretics were prescribed in 13.1% of patients. However, it was often impossible to adequately assess the regularity of the use, the dose, and the specific name of the drugs taken on an outpatient basis. Uric acid levels depending on treatment with different classes of medications are presented in Table 3 .
In light of the interesting results on the association of hyperuricemia with cardiovascular diseases in elderly people, we further attempted to study similar relationships in patients with CAD younger than 60 years. This group included 48 patients with atherosclerosis of the coronary arteries and clinical signs of coronary artery disease in the form of angina and/or myocardial infarction. Unlike older patients, the vast majority of patients from this group were men (82%), and only 18% were women. The age of patients ranged from 36 to 59 years old, 52.0 ± 5.9 years on average. The prevalence of hyperuricemia in this group was 39.6%. Comparative characteristics of two subgroups of patients younger than 60 years with the normal and elevated levels of uric acid are presented in Table 4 . Analysis of parameters of hyperuricemia and cardiovascular pathology in CAD patients younger than 60 years led to the following results. By contrast to older patients, the most significant relationship was observed between hyperuricemia and myocardial infarction (OR = 8.8; 95% CI = 2.0-38.9; p = 0.002). By analogy to older patients, a significant relationship was found between the presence of hyperuricemia and clinically significant chronic heart failure (OR = 6.9; 95% CI = 1.8-26.3; p = 0.003). There was no significant correlation between hyperuricemia and diabetes mellitus (OR = 1.2; 95% CI 0.3-4.9; p = 0.8). In addition, no correlation was found between the increased level of uric acid and the development of atrial fibrillation (p = 0.8), though the small number of patients with atrial fibrillation in this group of patients (6 cases in total) does not allow us to make definitive conclusions. There was also statistically significant association between the diameter of the left atrium and the level of uric acid in this group of patients (p = 0.03). The analysis of the relationship between hyperuricemia and stroke was not conducted since only two CAD patients younger than 60 years had a history of stroke.
Discussion
The obtained results demonstrate a significant prevalence of hyperuricemia in patients with coronary artery disease, both in seniors and in persons younger than 60 years. The number of patients with hyperuricemia in this study (37.4% and 39.6% among the older and younger patients, respectively) is somewhat higher than that reported in some other studies (2-21% on average) [14] . At the same time, our data are consistent with the results of several studies conducted mainly in South-East Asia which demonstrated a significant, up to 36-57%, prevalence of hyperuricemia in the population of older people [15, 16] . Such variability probably suggests significant differences (ethnic, genetic, lifestyle, etc.) of the studied groups of patients.
The specific features of the first group of patients studied in our works are, above all, their advanced age (86 years on average) and the significant prevalence of females. The prevalence of hyperuricemia is known to increase with age, and our data are in line with these previous observations. The significant prevalence of hyperuricemia in our study can be explained by the inclusion of patients with clinically significant cardiovascular diseases, the association of which with elevated uric acid levels has been repeatedly confirmed.
Somewhat unexpectedly, we observed a higher incidence of hyperuricemia in women (41%) compared with men (25% of cases), although, according to literature data, hyperuricemia is typically more often found in men. For the clinical interpretation of our results, the following concept can be proposed. Renal excretion of uric acid usually decreases under the influence of androgens and is stimulated by estrogens; therefore, hyperuricemia is more often observed in men, whereas in women it occurs predominantly in the period of menopause, with a decrease in estrogen levels [15] . All our women patients are older than 75 years, and accordingly, they have long been in postmenopause. At the same time, the level of androgens in men also decreases with age, although not as early and as quickly. Since the majority of men which participated in the study have reached the age of 85-90 years, it can be assumed that they have hypoandrogenemia, which could contribute to a decrease in serum uric acid levels. This hypothesis is in agreement with the results obtained by Lai et al. [15] who reported that the prevalence of hyperuricemia decreases with age in men (from 69% at the age of 65-69 to 48% in people over 80), and, on the contrary, increases in women.
In the studied group of patients, we revealed a number of significant relationships between hyperuricemia and cardiovascular diseases. The most significant association was found between the increased level of uric acid and clinically significant chronic heart failure; according to our data, the risk of CHF was increased by 5 times during hyperuricemia. Of note, this relationship was even more pronounced in the group of СAD patients younger than 60 years with hyperuricemia, in which the relative risk of CHF development was increased by 6 times. In clinical studies, hyperuricemia is often found in patients with CHF, and elevated uric acid levels are often considered as a marker for the progression of CHF and unfavorable prognosis of this pathology [12, [17] [18] [19] [20] [21] . The level of uric acid in patients with CHF can be elevated due to increased catabolism of purines caused by tissue hypoxia. Another possible factor is hyperactivation of xanthine oxidase which contributes to oxidative stress and stimulates cell apoptosis [17, 19] . Several recent studies have demonstrated that the inhibition of xanthine oxidase with allopurinol in patients with CHF and hyperuricemia can reduce the severity of symptoms, slow the progression of CHF, and improve the overall prognosis [18, 22] .
In older patients with hyperuricemia, an increase in the frequency of stroke was found, which is consistent with the results of other studies [9, 21] . The likely role of uric acid in the pathogenesis of stroke is associated with endothelial dysfunction, increased adhesion and aggregation activity of platelets and, most importantly, with arterial hypertension [9] . However, in our work, we did not observe significant differences in the levels of systolic and diastolic blood pressure in groups of patients with elevated and normal levels of uric acid.
Of significant theoretical and practical interest are the expressed relationship between hyperuricemia and atrial fibrillation, and the effect of hyperuricemia on the formation of left atrial dilatation, a key physiological factor for the development of atrial fibrillation. These data are consistent with the results of several recent studies which demonstrated that the risk of atrial fibrillation and left atrial dilatation is significantly increased in patients with elevated uric acid levels [8, [23] [24] [25] [26] . The reliable pathogenetic relationship between hyperuricemia and atrial fibrillation is not established yet; however, several concepts have been proposed. Some authors believe that the excess of uric acid, acting on the ion channels in the atrial myocytes, can cause electrophysiological disorders, leading, in turn, to the development of atrial fibrillation [25] . Other researchers believe that uric acid induces oxidative stress and inflammation that causes atrial remodeling, dilatation, and subsequent fibrillation [8] . In the elderly patients we examined dilatation of the left atrium which occurred in 73% of cases, which is natural for this age. But despite such a significant prevalence of this pathology, it was even more common in patients with hyperuricemia. A similar situation was observed for atrial fibrillation diagnosed in almost half (42.6%) of patients with hyperuricemia and only in a quarter of patients with normal levels of uric acid. As expected, in the studied group of older patients, overweight and obesity were observed significantly more often on the background of hyperuricemia. However, by contrast to some other studies, no significant differences in other components of the metabolic syndrome were found. Thus, diabetes mellitus in general was more common in patients with hyperuricemia, but these differences were not statistically significant.
In our study, an increase in uric acid levels was associated with a decrease in the nitrogen excretory kidney function and with deterioration of key indicators such as levels of creatinine and urea, and glomerular filtration rate. Although patients with clinically significant chronic kidney disease were not included in this study, this relationship may be due to the well-known decrease in the filtration function of the kidneys in aged people [15] .
Despite the interesting and partially unexpected results obtained in this study, there are a number of limitations. Unlike most similar studies, which included younger patients or healthy individuals, our study was performed on a specific population of patients-the elderly people with not only clinically significant cardiovascular diseases but also multiple comorbid pathology. The clinical features of the studied group of patients did not allow us to assess the role of dietary factors and lifestyle in the development of hyperuricemia and cardiovascular pathology. Another limitation of this study is its simultaneous, rather than prospective, character, and therefore, it was not possible to study the effect of uric acid concentration fluctuations on the progression of cardiovascular disease. Therefore, further studies are required to elucidate the role of uric acid as an independent risk factor for cardiovascular disease.
Conclusion
The obtained results indicate a significant prevalence of hyperuricemia in elderly people with CAD and hypertension, as well as in CAD patients younger than 60 years. A significant relationship was found between the increased levels of uric acid and the development of some cardiovascular diseases, primarily chronic heart failure, atrial fibrillation, and stroke. Of particular interest is the significant correlation between the serum level of uric acid and the diameter of the left atrium, one of the key factors in the development of atrial fibrillation. Despite some limitations, this study suggests important role of uric acid as an important risk factor for cardiovascular disease.
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